公开(公告)号：EP4441051A1

公开(公告)日：2024-10-09

申请号：EP22826087.3

申请日：2022-11-30

申请人： Boehringer Ingelheim International GmbH ,  Vanderbilt University

发明人： Broeker, Joachim ,  Ciulli, Aleissio ,  Diers, Emelyne ,  Gollner, Andreas ,  Goodwin-Tindall, Jake ,  Farnaby, William ,  Kofink, Christiane ,  Mantoulidis, Andreas ,  McLennan, Ross ,  Popow, Johannes ,  Schmiedel, Martin ,  Smethurst, Christian Alan Paul ,  Trainor, Nicole ,  Weinstabl, Harald ,  Zhong, Siying ,  Zollman, David ,  Abbott, Jason ,  Cui, Jianwen ,  Fesik, Stephen W. ,  Little, Andrew ,  Sarkar, Dhruba ,  Waterson, Alex ,  Hodges, Tim

IPC分类号： C07D417/14 ,  C07D413/14 ,  A61P35/00 ,  A61K31/506 ,  A61K31/4245

CPC分类号： C07D417/14 ,  C07D413/14 ,  A61P35/00

公开(公告)号：EP4292662A3

公开(公告)日：2024-02-21

申请号：EP23188050.1

申请日：2017-03-03

申请人： Vanderbilt University

发明人： Lee, Taekyu ,  Tarr, James C. ,  Jeon, Kyuok ,  Salovich, James M. ,  Shaw, Subrata ,  Veerasamy, Nagarathanam ,  Kim, Kwangho ,  Christov, Plamen P. ,  Olejniczak, Edward T. ,  Zhao, Bin ,  Fesik, Stephen W. ,  Bian, Zhiguo

IPC分类号： C07D487/04 ,  A61K31/407 ,  A61P35/00

摘要： The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

公开(公告)号：EP4292662A2

公开(公告)日：2023-12-20

申请号：EP23188050.1

申请日：2017-03-03

申请人： Vanderbilt University

发明人： Lee, Taekyu ,  Tarr, James C. ,  Jeon, Kyuok ,  Salovich, James M. ,  Shaw, Subrata ,  Veerasamy, Nagarathanam ,  Kim, Kwangho ,  Christov, Plamen P. ,  Olejniczak, Edward T. ,  Zhao, Bin ,  Fesik, Stephen W. ,  Bian, Zhiguo

IPC分类号： A61P35/00

摘要： The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.